Skip to main content
Erschienen in: Zeitschrift für Gerontologie und Geriatrie 1/2018

22.11.2016 | Reviews

Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes

verfasst von: Galia Jackobson, Narin Nard Carmel, Dor Lotan, Anjelika Kremer, Dan Justo, MD

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

A systematic review was conducted for all published case reports on drug-induced torsade de pointes (TdP) in elderly (≥80 years) patients to study if the administration of the offending agent was reckless. Overall, 61 reports on drug-induced TdP in patients aged 80–97 years were included in the analysis. Non-modifiable risk factors for drug-induced TdP (e.g. acute coronary syndrome, female gender and congestive heart failure), modifiable risk factors (e.g. hypokalemia, severe hypomagnesemia and digitalis toxicity) and reckless administration of a QT interval-prolonging agent (e.g. despite a known QT interval prolongation or a history of TdP, together with other QT interval prolonging agents in higher than recommended doses) were recorded in each case. Overall, 54 (88.5%) patients had non-modifiable risk factors for drug-induced TdP and 21 (34.4%) patients had modifiable risk factors. The administration of the offending agent was reckless in one half (n = 31; 50.8%) of the patients. The most prevalent reckless administration of a QT interval-prolonging agent was together with other QT interval-prolonging agents (n = 16; 51.6%) or despite QT interval prolongation (n = 8; 25.8%). In conclusion, although risk factors for drug-induced TdP are prevalent in elderly patients with drug-induced TdP, in approximately 50% of patients it appeared following a reckless administration of a QT interval-prolonging agent. In this population physicians should particularly avoid administration of two or more QT interval-prolonging agents simultaneously or administration of a QT interval-prolonging agent despite QT interval prolongation.
Literatur
2.
4.
Zurück zum Zitat Leier CV, Dei Cas L, Metra M (1994) Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 128:564–574CrossRefPubMed Leier CV, Dei Cas L, Metra M (1994) Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 128:564–574CrossRefPubMed
5.
Zurück zum Zitat Abete P, Testa G, Della-Morte D, Gargiulo G, Galizia G, de Santis D, Magliocca A, Basile C, Cacciatore F (2013) Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev 18:529–551CrossRefPubMed Abete P, Testa G, Della-Morte D, Gargiulo G, Galizia G, de Santis D, Magliocca A, Basile C, Cacciatore F (2013) Treatment for chronic heart failure in the elderly: current practice and problems. Heart Fail Rev 18:529–551CrossRefPubMed
6.
Zurück zum Zitat Maher RL, Hanlon J, Hajjar ER (2014) Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 13:57–65CrossRefPubMed Maher RL, Hanlon J, Hajjar ER (2014) Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 13:57–65CrossRefPubMed
7.
Zurück zum Zitat Reardon M, Malik M (1996) QT interval change with age in an overtly healthy older population. Clin Cardiol 19:949–952CrossRefPubMed Reardon M, Malik M (1996) QT interval change with age in an overtly healthy older population. Clin Cardiol 19:949–952CrossRefPubMed
8.
Zurück zum Zitat Esen AM, Barutcu I, Melek M, Kaya D, Onrat E, Batukan Esen O (2004) Comparison of QT interval duration and dispersion in elderly population versus healthy young subjects. Clin Auton Res 14:408–411CrossRefPubMed Esen AM, Barutcu I, Melek M, Kaya D, Onrat E, Batukan Esen O (2004) Comparison of QT interval duration and dispersion in elderly population versus healthy young subjects. Clin Auton Res 14:408–411CrossRefPubMed
10.
Zurück zum Zitat Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB (2002) Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 34:861–863CrossRefPubMed Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB (2002) Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 34:861–863CrossRefPubMed
11.
Zurück zum Zitat Justo D, Mardi T, Zeltser D (2004) Roxithromycin-induced torsades de pointes. Eur J Intern Med 15:326–327CrossRefPubMed Justo D, Mardi T, Zeltser D (2004) Roxithromycin-induced torsades de pointes. Eur J Intern Med 15:326–327CrossRefPubMed
12.
Zurück zum Zitat Samaha FF (1999) QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 107:528–529CrossRefPubMed Samaha FF (1999) QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 107:528–529CrossRefPubMed
13.
Zurück zum Zitat Fteha A, Fteha E, Haq S, Kozer L, Saul B, Kassotis J (2004) Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol 27:1449–1450CrossRefPubMed Fteha A, Fteha E, Haq S, Kozer L, Saul B, Kassotis J (2004) Gatifloxacin induced torsades de pointes. Pacing Clin Electrophysiol 27:1449–1450CrossRefPubMed
14.
Zurück zum Zitat Sekkarie MA (1997) Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 30:437–439CrossRefPubMed Sekkarie MA (1997) Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 30:437–439CrossRefPubMed
15.
Zurück zum Zitat Goss JE, Ramo BW, Blake K (1993) Torsades de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 53:2705CrossRef Goss JE, Ramo BW, Blake K (1993) Torsades de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 53:2705CrossRef
16.
Zurück zum Zitat Gitler B, Berger LS, Buffa SD (1994) Torsades de pointes induced by erythromycin. Chest 105:368–372CrossRefPubMed Gitler B, Berger LS, Buffa SD (1994) Torsades de pointes induced by erythromycin. Chest 105:368–372CrossRefPubMed
17.
Zurück zum Zitat Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338:344–345CrossRefPubMed Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC (1991) Torsades de pointes ventricular tachycardia and terodiline. Lancet 338:344–345CrossRefPubMed
18.
Zurück zum Zitat Herrmann HC, Kaplan LM, Bierer BE (1983) Q‑T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 51:904–906CrossRefPubMed Herrmann HC, Kaplan LM, Bierer BE (1983) Q‑T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 51:904–906CrossRefPubMed
19.
Zurück zum Zitat Matsis PP, Easthope RN (1994) Torsades de pointes ventricular tachycardia associated with terfenadine and paracetamol self medication. N Z Med J 369:402–403 Matsis PP, Easthope RN (1994) Torsades de pointes ventricular tachycardia associated with terfenadine and paracetamol self medication. N Z Med J 369:402–403
20.
Zurück zum Zitat McLeod AA, Thorogood S (1991) Torsades de pointes complicating treatment with terodiline. Br Med J 302:1469CrossRef McLeod AA, Thorogood S (1991) Torsades de pointes complicating treatment with terodiline. Br Med J 302:1469CrossRef
21.
Zurück zum Zitat Ng KS, Tham LS, Tan HH, Chia BL (2000) Cisapride and torsades de pointes in a pacemaker patient. PACE 23:130–132CrossRefPubMed Ng KS, Tham LS, Tan HH, Chia BL (2000) Cisapride and torsades de pointes in a pacemaker patient. PACE 23:130–132CrossRefPubMed
22.
Zurück zum Zitat Rezkalla M, Pochop C (1994) Erythromycin induced torsade de pointes: case report and review of the literature. S D J Med 47:161–164PubMed Rezkalla M, Pochop C (1994) Erythromycin induced torsade de pointes: case report and review of the literature. S D J Med 47:161–164PubMed
23.
Zurück zum Zitat Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC (2006) QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 163:325CrossRefPubMed Wilting I, Smals OM, Holwerda NJ, Meyboom RH, de Bruin ML, Egberts TC (2006) QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am J Psychiatry 163:325CrossRefPubMed
24.
Zurück zum Zitat Tei Y, Morita T, Inoue S, Miyata H (2004) Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 45:450–451CrossRefPubMed Tei Y, Morita T, Inoue S, Miyata H (2004) Torsades de pointes caused by a small dose of risperidone in a terminally ill cancer patient. Psychosomatics 45:450–451CrossRefPubMed
25.
Zurück zum Zitat Voigt L, Coromilas J, Saul BI, Kassotis J (2003) Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation – a case report. Angiology 54:229–231CrossRefPubMed Voigt L, Coromilas J, Saul BI, Kassotis J (2003) Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation – a case report. Angiology 54:229–231CrossRefPubMed
26.
Zurück zum Zitat Gowda RM, Punukollu G, Khan IA, Patlola RR, Tejani FH, Cosme-Thormann BF, Vasavada BC, Sacchi TJ (2002) Ibutilide-induced long QT syndrome and torsade de pointes. Am J Ther 9:527–529CrossRefPubMed Gowda RM, Punukollu G, Khan IA, Patlola RR, Tejani FH, Cosme-Thormann BF, Vasavada BC, Sacchi TJ (2002) Ibutilide-induced long QT syndrome and torsade de pointes. Am J Ther 9:527–529CrossRefPubMed
27.
Zurück zum Zitat Chou CC, Wu D (2001) Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 24:805–809PubMed Chou CC, Wu D (2001) Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 24:805–809PubMed
28.
Zurück zum Zitat Cammu G, Geelen P, Baetens P, De Vos J, Demeyer I (1999) Two cases of torsades de pointes caused by sotalol therapy. Resuscitation 40:49–51CrossRefPubMed Cammu G, Geelen P, Baetens P, De Vos J, Demeyer I (1999) Two cases of torsades de pointes caused by sotalol therapy. Resuscitation 40:49–51CrossRefPubMed
29.
Zurück zum Zitat Dancey D, Wulffhart Z, McEwan P (1997) Sotalol-induced torsades de pointes in patients with renal failure. Can J Cardiol 13:55–58PubMed Dancey D, Wulffhart Z, McEwan P (1997) Sotalol-induced torsades de pointes in patients with renal failure. Can J Cardiol 13:55–58PubMed
30.
Zurück zum Zitat Gould LA, Betzu R, Vacek T, Muller RT, Pradeep V, Scafa A (1990) Magnesium treatment of torsade de pointes: a case report. Angiology 41:577–581CrossRefPubMed Gould LA, Betzu R, Vacek T, Muller RT, Pradeep V, Scafa A (1990) Magnesium treatment of torsade de pointes: a case report. Angiology 41:577–581CrossRefPubMed
31.
Zurück zum Zitat Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT (1996) Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28:1556–1561CrossRefPubMed Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, January CT (1996) Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28:1556–1561CrossRefPubMed
32.
Zurück zum Zitat Carter JE Jr, Childers RW (1992) Torsade de pointes complicating acute myocardial infarction: the importance of autonomic dysfunction as assessed by heart rate variability. Clin Cardiol 15:769–772CrossRefPubMed Carter JE Jr, Childers RW (1992) Torsade de pointes complicating acute myocardial infarction: the importance of autonomic dysfunction as assessed by heart rate variability. Clin Cardiol 15:769–772CrossRefPubMed
33.
Zurück zum Zitat Kourgiannidis G, Chierchia GB, Wyffels E, Geelen P, Brugada P (2005) A case of monomorphic ventricular tachycardia? J Cardiovasc Electrophysiol 16:1014–1016CrossRefPubMed Kourgiannidis G, Chierchia GB, Wyffels E, Geelen P, Brugada P (2005) A case of monomorphic ventricular tachycardia? J Cardiovasc Electrophysiol 16:1014–1016CrossRefPubMed
34.
Zurück zum Zitat Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42:577–580CrossRefPubMed Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ (1992) Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 42:577–580CrossRefPubMed
35.
Zurück zum Zitat Lin JC, Quasny HA (1997) QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 17:626–630PubMed Lin JC, Quasny HA (1997) QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine. Pharmacotherapy 17:626–630PubMed
36.
Zurück zum Zitat Nagra BS, Ledley GS, Kantharia BK (2005) Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale. J Cardiovasc Pharmacol Ther 10:191–195CrossRefPubMed Nagra BS, Ledley GS, Kantharia BK (2005) Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale. J Cardiovasc Pharmacol Ther 10:191–195CrossRefPubMed
37.
Zurück zum Zitat Lim HE, Pak HN, Ahn JC, Song WH, Kim YH (2006) Torsade de pointes induced by short-term oral amiodarone therapy. Europace 8:1051–1053CrossRefPubMed Lim HE, Pak HN, Ahn JC, Song WH, Kim YH (2006) Torsade de pointes induced by short-term oral amiodarone therapy. Europace 8:1051–1053CrossRefPubMed
38.
Zurück zum Zitat Raviña T, Raviña P, Gutierrez J (2007) Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I. Int J Cardiol 116:416–420CrossRefPubMed Raviña T, Raviña P, Gutierrez J (2007) Acquired long QT syndrome: risperidone-facilitated triggered activity and Torsades de Pointes during complete AV block. I. Int J Cardiol 116:416–420CrossRefPubMed
39.
Zurück zum Zitat Kanjanauthai S, Kanluen T, Chareonthaitawee P (2008) Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 131:e33–e34CrossRefPubMed Kanjanauthai S, Kanluen T, Chareonthaitawee P (2008) Citalopram induced torsade de pointes, a rare life threatening side effect. Int J Cardiol 131:e33–e34CrossRefPubMed
40.
Zurück zum Zitat Dubrey SW, Grocott-Mason R (2007) Drug-induced QT prolongation: consequences and current dilemma. Br J Hosp Med (Lond) 68:50–51CrossRef Dubrey SW, Grocott-Mason R (2007) Drug-induced QT prolongation: consequences and current dilemma. Br J Hosp Med (Lond) 68:50–51CrossRef
41.
Zurück zum Zitat Huang BH, Wu CH, Hsia CP, Yin Chen C (2007) Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 30:1579–1582CrossRefPubMed Huang BH, Wu CH, Hsia CP, Yin Chen C (2007) Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 30:1579–1582CrossRefPubMed
42.
Zurück zum Zitat Aktas MK, Shah AH, Akiyama T (2007) Dofetilide-induced long QT and torsades de pointes. Ann Noninvasive Electrocardiol 12:197–202CrossRefPubMed Aktas MK, Shah AH, Akiyama T (2007) Dofetilide-induced long QT and torsades de pointes. Ann Noninvasive Electrocardiol 12:197–202CrossRefPubMed
43.
Zurück zum Zitat Altin T, Ozcan O, Turhan S, Ongun Ozdemir A, Akyurek O, Karaoguz R, Guldal M (2007) Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 23:907–908CrossRefPubMedPubMedCentral Altin T, Ozcan O, Turhan S, Ongun Ozdemir A, Akyurek O, Karaoguz R, Guldal M (2007) Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 23:907–908CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Dale KM, Lertsburapa K, Kluger J, White CM (2007) Moxifloxacin and torsade de pointes. Ann Pharmacother 41:336–340CrossRefPubMed Dale KM, Lertsburapa K, Kluger J, White CM (2007) Moxifloxacin and torsade de pointes. Ann Pharmacother 41:336–340CrossRefPubMed
45.
Zurück zum Zitat Foley P, Kalra P, Andrews N (2008) Amiodarone – avoid the danger of torsade de pointes. Resuscitation 76:137–141CrossRefPubMed Foley P, Kalra P, Andrews N (2008) Amiodarone – avoid the danger of torsade de pointes. Resuscitation 76:137–141CrossRefPubMed
46.
Zurück zum Zitat Takaya T, Okamoto M, Yodoi K, Hata K, Kijima Y, Nakajima H, Nishikawa Y, Kita T, Ito M, Seo T, Kawashima S (2009) Torsades de pointes with QT prolongation related to donepezil use. J Cardiol 54:507–511CrossRefPubMed Takaya T, Okamoto M, Yodoi K, Hata K, Kijima Y, Nakajima H, Nishikawa Y, Kita T, Ito M, Seo T, Kawashima S (2009) Torsades de pointes with QT prolongation related to donepezil use. J Cardiol 54:507–511CrossRefPubMed
47.
Zurück zum Zitat Miyamoto K, Kawai H, Aoyama R, Watanabe H, Suzuki K, Suga N, Kitagawa W, Miura N, Nishikawa K, Imai H (2010) Torsades de pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice. Clin Exp Nephrol 14:164–167CrossRefPubMed Miyamoto K, Kawai H, Aoyama R, Watanabe H, Suzuki K, Suga N, Kitagawa W, Miura N, Nishikawa K, Imai H (2010) Torsades de pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice. Clin Exp Nephrol 14:164–167CrossRefPubMed
48.
Zurück zum Zitat Michiels V, Miljoen H, Vrints C (2009) Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes. Acta Cardiol 64:839–842CrossRefPubMed Michiels V, Miljoen H, Vrints C (2009) Gastroenteritis with severe consequences: a case of sotalol-induced torsades de pointes. Acta Cardiol 64:839–842CrossRefPubMed
49.
Zurück zum Zitat Tanaka A, Koga S, Hiramatsu Y (2009) Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and torsade de pointes. Intern Med 48:1219–1223CrossRefPubMed Tanaka A, Koga S, Hiramatsu Y (2009) Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and torsade de pointes. Intern Med 48:1219–1223CrossRefPubMed
50.
51.
Zurück zum Zitat Fayssoil A, Issi J, Guerbaa M, Raynaud JC, Heroguelle V (2011) Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris) 60:165–168CrossRef Fayssoil A, Issi J, Guerbaa M, Raynaud JC, Heroguelle V (2011) Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris) 60:165–168CrossRef
52.
Zurück zum Zitat Yoshioka R, Sakabe M, Toyama H, Muro Y, Fujiki A (2011) Torsades de pointes induced by garenoxacin in association with pacing failure in an elderly woman with VDD pacemaker. J Cardiol Cases 3:e62–e64CrossRef Yoshioka R, Sakabe M, Toyama H, Muro Y, Fujiki A (2011) Torsades de pointes induced by garenoxacin in association with pacing failure in an elderly woman with VDD pacemaker. J Cardiol Cases 3:e62–e64CrossRef
53.
Zurück zum Zitat Abo-Salem E, Nugent K, Chance W (2011) Antibiotic-induced cardiac arrhythmia in elderly patients. J Am Geriatr Soc 59:1747–1749CrossRefPubMed Abo-Salem E, Nugent K, Chance W (2011) Antibiotic-induced cardiac arrhythmia in elderly patients. J Am Geriatr Soc 59:1747–1749CrossRefPubMed
54.
Zurück zum Zitat Agosti S, Casalino L, Bertero G, Barsotti A, Brunelli C, Morelloni S (2012) A dangerous fruit juice. Am J Emerg Med 30:248.e5–248.e8CrossRef Agosti S, Casalino L, Bertero G, Barsotti A, Brunelli C, Morelloni S (2012) A dangerous fruit juice. Am J Emerg Med 30:248.e5–248.e8CrossRef
55.
Zurück zum Zitat Hadano Y, Ogawa H, Wakeyama T, Iwami T, Kimura M, Mochizuki M, Akashi S, Miyazaki Y, Nakashima T, Shimizu A (2013) Donepezil-induced torsades de pointes without QT prolongation. J Cardiol Cases 8:e69–e71CrossRef Hadano Y, Ogawa H, Wakeyama T, Iwami T, Kimura M, Mochizuki M, Akashi S, Miyazaki Y, Nakashima T, Shimizu A (2013) Donepezil-induced torsades de pointes without QT prolongation. J Cardiol Cases 8:e69–e71CrossRef
57.
Zurück zum Zitat Kukla P, Baranchuk A, Jastrzębski M, Bryniarski L, Baranowski R (2013) Giant drug-induced QT prolongation > 800 ms with alternans of terminal portion of T wave and J wave in a normothermic patient. Kardiol Pol 71:1306–1307CrossRefPubMed Kukla P, Baranchuk A, Jastrzębski M, Bryniarski L, Baranowski R (2013) Giant drug-induced QT prolongation > 800 ms with alternans of terminal portion of T wave and J wave in a normothermic patient. Kardiol Pol 71:1306–1307CrossRefPubMed
58.
Zurück zum Zitat Mittal SR (2014) Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine. J Assoc Physicians India 62:426–427PubMed Mittal SR (2014) Slow junctional rhythm, QTc prolongation and transient torsades de-pointes following combined use of Ivabradine, Diltiazem and Ranolazine. J Assoc Physicians India 62:426–427PubMed
59.
Zurück zum Zitat Liszkai G, Fazekas T (1998) Quinidine-induced syncope simulating transient cerebral ischemic attack. Orv Hetil 139:1425–1428PubMed Liszkai G, Fazekas T (1998) Quinidine-induced syncope simulating transient cerebral ischemic attack. Orv Hetil 139:1425–1428PubMed
60.
Zurück zum Zitat Haffner S, Lapp H, Thürmann PA (2002) Adverse drug reactions – case report. Dtsch Med Wochenschr 127:1021CrossRefPubMed Haffner S, Lapp H, Thürmann PA (2002) Adverse drug reactions – case report. Dtsch Med Wochenschr 127:1021CrossRefPubMed
61.
Zurück zum Zitat Sieber C, Weiss P, Follath F (1990) Hemiparesis and torsade de pointes under low-dose sotalol therapy. Schweiz Med Wochenschr 120:1397–1399PubMed Sieber C, Weiss P, Follath F (1990) Hemiparesis and torsade de pointes under low-dose sotalol therapy. Schweiz Med Wochenschr 120:1397–1399PubMed
62.
Zurück zum Zitat Arfiero S, Ometto R, Vincenzi M (1990) Prolongation of the QT interval and torsade de pointes caused by ketanserin. G Ital Cardiol 20:869–872PubMed Arfiero S, Ometto R, Vincenzi M (1990) Prolongation of the QT interval and torsade de pointes caused by ketanserin. G Ital Cardiol 20:869–872PubMed
63.
Zurück zum Zitat Nakatani S, Taniike M, Makino N, Egami Y, Shutta R, Tanouchi J, Nishino M (2014) A case of sudden cardiac death due to Pilsicainide-induced torsades de pointes. Korean Circ J 44:122–124CrossRefPubMedPubMedCentral Nakatani S, Taniike M, Makino N, Egami Y, Shutta R, Tanouchi J, Nishino M (2014) A case of sudden cardiac death due to Pilsicainide-induced torsades de pointes. Korean Circ J 44:122–124CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Kitt J, Irons R, Al-Obaidi M, Missouris C (2015) A case of donepezil-related torsades de pointes. BMJ Case Rep. doi:10.1136/bcr-2015-211900 Kitt J, Irons R, Al-Obaidi M, Missouris C (2015) A case of donepezil-related torsades de pointes. BMJ Case Rep. doi:10.1136/bcr-2015-211900
65.
Zurück zum Zitat García-Fuertes D, Villanueva-Fernández E, Crespín-Crespín M (2016) Drug-induced long-QT and torsades de pointes in elderly polymedicated patients. Arq Bras Cardiol 106:156–159PubMedPubMedCentral García-Fuertes D, Villanueva-Fernández E, Crespín-Crespín M (2016) Drug-induced long-QT and torsades de pointes in elderly polymedicated patients. Arq Bras Cardiol 106:156–159PubMedPubMedCentral
66.
Zurück zum Zitat Gurbuz AS, Ozturk S, Acar E, Efe SC, Akgun T, Kilicgedik A, Guler A, Kirma C (2015) Acquired long QT syndrome and torsades de pointes related to donepezil use in a patient with Alzheimer disease. Egypt Heart J. doi:10.1016/j.ehj.2015.07.004 Gurbuz AS, Ozturk S, Acar E, Efe SC, Akgun T, Kilicgedik A, Guler A, Kirma C (2015) Acquired long QT syndrome and torsades de pointes related to donepezil use in a patient with Alzheimer disease. Egypt Heart J. doi:10.​1016/​j.​ehj.​2015.​07.​004
67.
Zurück zum Zitat Stein LB, Dabezies MA, Silverman M, Brozena SC (1992) Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin. J Clin Gastroenterol 15:171–174CrossRefPubMed Stein LB, Dabezies MA, Silverman M, Brozena SC (1992) Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin. J Clin Gastroenterol 15:171–174CrossRefPubMed
68.
Zurück zum Zitat Thompson C, Tsiperfal A (2003) Why is the QT interval measurement so critical when evaluating an ECG rhythm? Prog Cardiovasc Nurs 18:158–159CrossRefPubMed Thompson C, Tsiperfal A (2003) Why is the QT interval measurement so critical when evaluating an ECG rhythm? Prog Cardiovasc Nurs 18:158–159CrossRefPubMed
69.
Zurück zum Zitat Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM (2004) Famotidine and long QT syndrome. Am J Cardiol 93:1325–1327CrossRefPubMed Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman MM (2004) Famotidine and long QT syndrome. Am J Cardiol 93:1325–1327CrossRefPubMed
70.
Zurück zum Zitat Asajima H, Sekiguchi Y, Matsushima S, Saito N, Saito T (2008) QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 66:896–897CrossRefPubMedPubMedCentral Asajima H, Sekiguchi Y, Matsushima S, Saito N, Saito T (2008) QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 66:896–897CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat Siddique SM, Shariff N, Vesuwala N, Hafiz T (2009) Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med 150:502–504CrossRefPubMed Siddique SM, Shariff N, Vesuwala N, Hafiz T (2009) Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med 150:502–504CrossRefPubMed
72.
Zurück zum Zitat Fisher AA, Davis MW (2008) Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 42:278–283CrossRefPubMed Fisher AA, Davis MW (2008) Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 42:278–283CrossRefPubMed
73.
Zurück zum Zitat Bazzet HC (1920) An analysis of time relations of echocardiograms. Heart 7:353–367 Bazzet HC (1920) An analysis of time relations of echocardiograms. Heart 7:353–367
74.
Zurück zum Zitat Hauptman PJ, McCann P, Romero JM, Mayo M (2013) Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Intern Med 173:1552–1554CrossRefPubMed Hauptman PJ, McCann P, Romero JM, Mayo M (2013) Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Intern Med 173:1552–1554CrossRefPubMed
75.
Zurück zum Zitat Viskin S (2000) Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 11:593–600CrossRefPubMed Viskin S (2000) Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J Cardiovasc Electrophysiol 11:593–600CrossRefPubMed
78.
Zurück zum Zitat Choy AMJ, Darbar D, Dell’Orto S, Roden DM (1999) Exaggerated QT prolongation and cardioversion of atrial fibrillation. J Am Coll Cardiol 34:396–401CrossRefPubMed Choy AMJ, Darbar D, Dell’Orto S, Roden DM (1999) Exaggerated QT prolongation and cardioversion of atrial fibrillation. J Am Coll Cardiol 34:396–401CrossRefPubMed
79.
80.
Zurück zum Zitat Winkler C, Funk M, Schindler DM, Hemsey JZ, Lampert R, Drew BJ (2013) Arrhythmias in patients with acute coronary syndrome in the first 24 hours of hospitalization. Heart Lung 42:422–427CrossRefPubMed Winkler C, Funk M, Schindler DM, Hemsey JZ, Lampert R, Drew BJ (2013) Arrhythmias in patients with acute coronary syndrome in the first 24 hours of hospitalization. Heart Lung 42:422–427CrossRefPubMed
81.
Zurück zum Zitat Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857–865CrossRefPubMed Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857–865CrossRefPubMed
82.
Zurück zum Zitat Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590–2597CrossRefPubMed Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590–2597CrossRefPubMed
84.
Zurück zum Zitat Paran Y, Mashav N, Henis O, Swartzon M, Arbel Y, Justo D (2008) Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 8:260–265PubMed Paran Y, Mashav N, Henis O, Swartzon M, Arbel Y, Justo D (2008) Drug-induced torsades de pointes in patients aged 80 years or more. Anadolu Kardiyol Derg 8:260–265PubMed
86.
Zurück zum Zitat Su HM, Chiu HC, Lin TH, Voon WC, Liu HW, Lai WT (2006) Longitudinal study of the ageing trends in QT interval and dispersion in healthy elderly subjects. Age Ageing 35:636–638CrossRefPubMed Su HM, Chiu HC, Lin TH, Voon WC, Liu HW, Lai WT (2006) Longitudinal study of the ageing trends in QT interval and dispersion in healthy elderly subjects. Age Ageing 35:636–638CrossRefPubMed
87.
Zurück zum Zitat Lubart E, Segal R, Megid S, Yarovoy A, Leibovitz A (2012) QT interval disturbances in elderly residents of long-term care facilities. Isr Med Assoc J 14:244–246PubMed Lubart E, Segal R, Megid S, Yarovoy A, Leibovitz A (2012) QT interval disturbances in elderly residents of long-term care facilities. Isr Med Assoc J 14:244–246PubMed
88.
Zurück zum Zitat Lubart E, Segal R, Yearovoi A, Fridenson A, Baumoehl Y, Leibovitz A (2009) QT interval disturbances in hospitalized elderly patients. Isr Med Assoc J 11:147–150PubMed Lubart E, Segal R, Yearovoi A, Fridenson A, Baumoehl Y, Leibovitz A (2009) QT interval disturbances in hospitalized elderly patients. Isr Med Assoc J 11:147–150PubMed
89.
Zurück zum Zitat Goutelle S, Sidolle E, Ducher M, Caron J, Timour Q, Nony P, Gouraud A (2014) Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study. Drugs Aging 31:601–609CrossRefPubMed Goutelle S, Sidolle E, Ducher M, Caron J, Timour Q, Nony P, Gouraud A (2014) Determinants of torsades de pointes in older patients with drug-associated long QT syndrome: a case-control study. Drugs Aging 31:601–609CrossRefPubMed
90.
Zurück zum Zitat Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, Usdin Yasuda S, Dans PE, Wright A, Califf RM, Woosley RL, Schulman KA (2003) Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 114:135–141CrossRefPubMed Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, Usdin Yasuda S, Dans PE, Wright A, Califf RM, Woosley RL, Schulman KA (2003) Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 114:135–141CrossRefPubMed
91.
Zurück zum Zitat Tay KY, Ewald MB, Bourgeois FT (2014) Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf 23:9–17CrossRefPubMed Tay KY, Ewald MB, Bourgeois FT (2014) Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf 23:9–17CrossRefPubMed
92.
Zurück zum Zitat Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM, REPOSI Investigators (2016) Prevalence and risk factors associated with use of QT-prolonging drugs in hospitalized older people. Drugs Aging 33:53–61CrossRefPubMed Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM, REPOSI Investigators (2016) Prevalence and risk factors associated with use of QT-prolonging drugs in hospitalized older people. Drugs Aging 33:53–61CrossRefPubMed
93.
Zurück zum Zitat Woosley RL, Romero KA. www.Crediblemeds.org, QTdrugs List, [Accessed on March 12, 2016], AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755. Woosley RL, Romero KA. www.​Crediblemeds.​org, QTdrugs List, [Accessed on March 12, 2016], AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755.
94.
Zurück zum Zitat Heist EK, Ruskin JN (2005) Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians. Heart Rhythm 2(2 Suppl):S1–S8CrossRefPubMed Heist EK, Ruskin JN (2005) Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians. Heart Rhythm 2(2 Suppl):S1–S8CrossRefPubMed
95.
Zurück zum Zitat Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurión OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D (2005) Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2:569–574CrossRefPubMed Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurión OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D (2005) Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2:569–574CrossRefPubMed
96.
Zurück zum Zitat Garg A, Lehmann MH (2013) Prolonged QT interval diagnosis suppression by a widely used computerized ECG analysis system. Circ Arrhythm Electrophysiol 6:76–83CrossRefPubMed Garg A, Lehmann MH (2013) Prolonged QT interval diagnosis suppression by a widely used computerized ECG analysis system. Circ Arrhythm Electrophysiol 6:76–83CrossRefPubMed
97.
Zurück zum Zitat Goldenberg I, Moss AJ, Zareba W (2006) QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol 17:333–336CrossRefPubMed Goldenberg I, Moss AJ, Zareba W (2006) QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol 17:333–336CrossRefPubMed
98.
Zurück zum Zitat Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D (2010) Preferred QT correction formula for the assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 21:905–913PubMed Chiladakis J, Kalogeropoulos A, Arvanitis P, Koutsogiannis N, Zagli F, Alexopoulos D (2010) Preferred QT correction formula for the assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 21:905–913PubMed
99.
Zurück zum Zitat Stancampiano FF, Palmer WC, Getz TW, Serra-Valentin NA, Sears SP, Seeger KM, Pagan RJ, Racho RG, Ray JC, Snipelisky DF, Mentel JJ, Diehl NN, Heckman MG (2015) Rare incidence of ventricular tachycardia and torsades de pointes in hospitalized patients with prolonged QT who later received levofloxacin: a retrospective study. Mayo Clin Proc 90:606–612CrossRefPubMed Stancampiano FF, Palmer WC, Getz TW, Serra-Valentin NA, Sears SP, Seeger KM, Pagan RJ, Racho RG, Ray JC, Snipelisky DF, Mentel JJ, Diehl NN, Heckman MG (2015) Rare incidence of ventricular tachycardia and torsades de pointes in hospitalized patients with prolonged QT who later received levofloxacin: a retrospective study. Mayo Clin Proc 90:606–612CrossRefPubMed
100.
Zurück zum Zitat Shah RR (2004) Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 27:145–172CrossRefPubMed Shah RR (2004) Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 27:145–172CrossRefPubMed
101.
Zurück zum Zitat Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP, Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA) (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 13:1077–1109CrossRefPubMed Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP, Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA) (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 13:1077–1109CrossRefPubMed
Metadaten
Titel
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes
verfasst von
Galia Jackobson
Narin Nard Carmel
Dor Lotan
Anjelika Kremer
Dan Justo, MD
Publikationsdatum
22.11.2016
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Gerontologie und Geriatrie / Ausgabe 1/2018
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI
https://doi.org/10.1007/s00391-016-1155-5

Weitere Artikel der Ausgabe 1/2018

Zeitschrift für Gerontologie und Geriatrie 1/2018 Zur Ausgabe